RIP assays indicated that TUG1 binds EHMT2 in AML cells, with increased binding in HL60/ADR and KG-1/ADR cells, which was reduced upon ALKBH5 silencing (P < 0.01, Figure 4B). Here, TUG1 is linked to acute myeloid leukemia.